In a filing, Immuneering Corp revealed its Director Feinberg Peter acquired Company’s shares for reported $50025.0 on Oct 03 ’25. In the deal valued at $6.67 per share,7,500 shares were bought. As a result of this transaction, Feinberg Peter now holds 156,766 shares worth roughly $0.96 million.
Then, Morales Mallory bought 300 shares, generating $1,917 in total proceeds. Upon buying the shares at $6.39, the Chief Accounting Officer now owns 27,533 shares.
Before that, Neufeld Leah R bought 800 shares. Immuneering Corp shares valued at $5,103 were divested by the CHIEF PEOPLE OFFICER at a price of $6.38 per share. As a result of the transaction, Neufeld Leah R now holds 23,344 shares, worth roughly $0.14 million.
Morgan Stanley downgraded its Immuneering Corp [IMRX] rating to an Underweight from a an Equal-weight in a research note published recently. A number of analysts have revised their coverage, including Needham’s analysts, who remained covering the stock and in mid March has reiterated a ‘”a Buy”‘ rating for it. TD Cowen also remained covering IMRX and has decreased its forecast on March 15, 2024 with a “Market perform” recommendation from previously “an Outperform” rating. Jefferies revised its rating on March 15, 2024. It rated IMRX as “a Hold” which previously was an “a Buy”.
Price Performance Review of IMRX
On Monday, Immuneering Corp [NASDAQ:IMRX] saw its stock jump 0.16% to $6.14. Over the last five days, the stock has lost -2.23%. Immuneering Corp shares have risen nearly 180.37% since the year began. Nevertheless, the stocks have risen 179.09% over the past one year.
How much short interest is there in Immuneering Corp?
A steep rise in short interest was recorded in Immuneering Corp stocks on 2025-09-30, growing by 4.45 million shares to a total of 6.28 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 1.83 million shares. There was a rise of 70.85%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 01, 2023 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $20 price target.
